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monary diseaseAbstract Background: Cardiovascular diseases (CVDs) remain a major leading cause of morbid-
ity and mortality in patients with chronic obstructive pulmonary disease (COPD). Increased aortic
stiffness is an independent predictor of cardiovascular disease. Microalbuminuria (MAU) reﬂects
increased permeability of the glomerulus, usually due to microvascular damage and suggested as
an early prognostic cardiovascular marker. So this study was done to determine the prevalence
of aortic stiffness in patients with COPD and to evaluate the relationship of MAU levels with
the degree of aortic stiffness.
Subjects and methods: This study was done at Respirology, Cardiology, Internal Medicine, and
Clinical Pathology Departments, Farwaniya Hospital, Ministry of Health, State of Kuwait in the
period between July 2013 and October 2014. A total 60 patients was distributed into 38 patients
with COPD (group 1) and 22 control subjects (group 2). Patients with COPD and controls under-
went spirometry, blood pressure, aortic stiffness assessment using aortic pulse wave velocity
(aPWV) study and provided a spot urine sample for MAU measurement.
Results: Patients with COPD (group 1) had increased aortic stiffness compared with matched
controls (group 2) 11.2 ± 2.3 vs. 7.8 ± 1.5 m/s, P< 0.05. Patients with GOLD III and IV had sig-
niﬁcant higher aPWV values as compared to patients with GOLD I and II (P< 0.05). Multiple
logistic regression analyses revealed that the adjusted odds ratios of having MAU for aPWV quar-
tile III and IV were 6.38 (95% conﬁdence interval: 2.37–13.2) and 6.58 (95% conﬁdence interval:
1.59–22.0) respectively, P< 0.05.ressure;
rculosis.
542 A. Refaat et al.Conclusions: COPD is associated with increased aortic stiffness. MAU is independently related
to aortic stiffness in patients with COPD. Further studies are necessary to investigate whether MAU
could be an effective biomarker of aortic stiffness and potential cardiovascular compromise in
patients with COPD.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cardiovascular diseases (CVDs) remain a major leading cause
of morbidity and mortality in patients with chronic obstructive
pulmonary disease (COPD) and this appears to be independent
of established risks such as smoking, gender and age [1]. The
biological mechanisms of increased cardiovascular risk in
COPD and cardiovascular disease are poorly understood.
Current studies proposed that systemic inﬂammation and
oxidative stress in COPD patients may contribute to the
endothelial dysfunction and atherosclerosis [2,3]. Systemic
inﬂammation can stimulate the remodelling process with
degradation of elastic ﬁbres in the arterial wall and replace-
ment by collagen. This will lead to increased arterial stiffness
and greater central aortic systolic pressures with increased
afterload and risk of CVD. Additionally, the renal vascular
beds will be susceptible to the increased pulsatile ﬂow due to
the reduced buffering capacity of the large arteries [4].
Microalbuminuria (MAU) reﬂects increased permeability of
the glomerulus, usually due to microvascular damage and sug-
gested as an early prognostic cardiovascular marker [5]. The
proportion of patients with COPD having co-existent renal
impairment has been highlighted. Casanova et al. [6] demon-
strated increased urinary albumin creatinine ratio in patients
with COPD compared to healthy smokers, which was related
to hypoxaemia and systolic blood pressure. Other studies
[7,8] hypothesized that the increased aortic stiffness in patients
with COPDwas related to the subclinical glomerular injury and
could be related to the decline of renal function.
Increased central arterial stiffness in patients with COPD
may explain the excess cardiovascular morbidity and mortality
in these patients. However, a limited number of studies have
evaluated the presence of aortic stiffness in patients with
COPD and the association of MAU was not considered. So
this study was done to determine the prevalence of aortic stiff-
ness in patients with COPD and to evaluate the relationship of
MAU levels with the degree of aortic stiffness.
Subjects and methods
This study was done at Respirology, Cardiology, Internal
Medicine, and Clinical Pathology Departments, Farwaniya
Hospital, Ministry of Health, State of Kuwait in the period
between July 2013 and October 2014. Demographic data and
a full medical and therapeutic history were collected at study
entry for all enrolled subjects. A total 60 patients were dis-
tributed into 38 patients with COPD (group 1) and 22 control
subjects (group 2). All patients with COPD were older than
40 years with a post-bronchodilator forced expiratory volume
in ﬁrst second (FEV1) to forced vital capacity (FVC) ratio of
0.70 or less with partial reversibility using 400 lg salbutamol(increase in FEV1 of 612% or 200 ml) [9]. The patients were
studied at clinical stability, deﬁned as no change in regular
therapy, no requirement for antibiotics and/or oral corticos-
teroids in the preceding 6 weeks and no change in symptoms
beyond day to day variation. The St George’s Respiratory
Questionnaire (SGRQ) was performed [10]. The Global initia-
tive for chronic Obstructive Lung Disease (GOLD) stage of
airﬂow obstruction was used to classify patients into four
GOLD stages I-IV based on post-bronchodilator FEV1 levels.
These are mild (GOLD-1, FEV1P 80% of predicted), moder-
ate (GOLD-2, 50% 6 FEV1 < 80% of predicted), severe
(GOLD-3, 30% 6 FEV1 < 50% of predicted) and very severe
(GOLD-4, FEV1 < 30% of predicted) according to the Global
Initiative against Chronic Obstructive Lung Disease (GOLD)
[9]. Another 22 subjects over 40 years of age with a smoking
history (more than 10 pack years) were also recruited as the
control group (group 2). Pack-years were calculated, by
multiplying the number of years of smoking by the average
number of cigarettes smoked per day and dividing by 20
[11]. All of control subjects had no evidence of airways
obstruction or history of respiratory disease.
Exclusion criteria
Patients with concomitant renal or presence of macroalbumin-
uria (urinary albumin to creatinine ratio >300 mg/g), cardio-
vascular and pulmonary diseases were excluded. Also, those
with known alpha-1-antitrypsin deﬁciency, active or suspected
malignancy or terminal disease, hypertension, diabetes mellitus
or those with systemic inﬂammatory diseases (e.g., rheumatoid
arthritis, inﬂammatory bowel disease) were also excluded.
Electrocardiographic and Echocardiographic Studies were per-
formed to rule out any cardiac disease.
Pulmonary function measurements
Spirometry was performed according to the American
Thoracic Society standards, using Jaeger Masterscreen full
PFT system (CareFusion, Germany). FEV1, FVC, and
FEV1: FVC ratio were determined. Total lung capacity
(TLC, L) and residual volume (RV, L) were obtained by con-
stant volume, different-pressure body plethysmography and
expressed as percent of the predicted value. Air trapping was
deﬁned as increased RV/TLC and RV (>0.4 and >140% pre-
dicted, respectively): TLC values >120% predicted were
indicative of lung hyperinﬂation [12].
Cardiovascular measurements
All subjects underwent complete echo-Doppler evaluation uti-
lizing the two-dimensional (2-D), M-mode, Doppler and tissue
Aortic stiffness and microalbuminuria in patients with COPD 543Doppler echocardiographic techniques. Left ventricular ejec-
tion fraction was calculated in 2D-mode, in the apical 2- and
4-chamber apical views, using the Simpson biplane method.
Early diastolic (E0) mitral annular velocity was measured and
correcting transmitral E wave for the inﬂuence of myocardial
relaxation (i.e. E/E0ratio) was calculated.
Aortic stiffness and peripheral vascular testing were done in
the morning after an overnight fast from food and cigarette
smoking for at least 8 h. Also, all subjects were directed to stop
vasoactive medications for 2 h, bronchodilator therapy for 6 h,
and caffeine for 3 h prior to the measurements and speaking or
sleeping were not allowed during measurements. All tests were
done in a temperature-controlled quiet room in resting supine
position at 15. Heart rate (HR) and peripheral blood pressure
(BP) were initially measured and pulse pressure (PP) (systolic
BP–diastolic BP) and mean arterial pressure (MAP) (1/3Figure 1 Aortic pulse wave velocity measurement: aPWV calculated
difference in time of pressure wave arrival between the carotid (
electrocardiogram.
Figure 2 Hemodynamic changes in arterial stiffness; (A) In normal a
In arterial stiffness: due to increased aPWV, forward wave and reﬂect(systolic BP–diastolic BP) + DBP) were calculated. After
15 min of rest, aortic pulse wave velocity (aPWV) was mea-
sured using Vicorder device (Skidmore Medical, Bristol,
UK), by placing a neckpad (for measurement of right common
carotid artery pulse) and a blood pressure cuff around the
upper right thigh (for measurement of right common femoral
pulse) and then aortic path length (the length between the
cuffs) was measured. The cuffs were inﬂated simultaneously
to 65 mmHg and 2 waveforms were simultaneously recorded.
This procedure allowed calculation of the systolic pressure
wave transit time and aPWV by the system software. Faster
wave transit times reﬂect stiffer arteries (Fig. 1). With the inte-
gral software, Augmentation pressure is the difference between
the systolic peak (forward wave) and ﬁrst systolic inﬂection
(reﬂected wave) pressures. This difference divided by the pulse
pressure generates the augmentation index (Fig. 2) [13].by dividing the distance (d) between the two arterial sites by the
t1) and femoral artery (t2) referenced to the R wave of the
ortic pulse waveform: forward wave precedes backward wave, (B)
ed wave are integrated producing augmented pulse pressure.
544 A. Refaat et al.Biochemical assays
Arterial blood gases were measured by arterial puncture, in the
morning, sitting at rest (15 min), breathing room air for at
least 45 min. A fasting venous blood was taken for measure-
ment of fasting glucose, creatinine, triglycerides, total choles-
terol, HDL-cholesterol and LDL-cholesterol. Spot morning
urine sample was collected for urinary albumin and creatinine
to determine albumin/creatinine ratio (ACR). To deﬁne MAU,
we used the ACR cut-off values of 30–300 mg/g for both men
and women. Normoalbuminuria (NAU) was deﬁned as the
ACR of less than 30 mg/g and macroalbuminuria (or overt
proteinuria) was deﬁned as the ACR of more than 300 mg/g
[14]. All analytes were measured on the Olympus AU2700 plat-
form (Beckman Coulter, USA) according to manufacturer’s
settings. The baseline renal function was assessed based on
estimated glomerular ﬁltration rate (eGFR) using Cockcroft-
Gault formula (creatinine clearance = (140  age) · (Weight
in kg) · (0.85 if female)/(72 · Cr in mg/dl)) [15].
Anthropometry
Height was obtained with subjects standing barefoot and was
determined to the nearest 0.5 cm and weight was measured to
the nearest 0.1 kg. Body mass index (BMI) was calculated in
kg/m2. A low BMI was deﬁned as less than 18.5 kg/m2; while
BMI greater than 25 kg/m2 is considered overweight and
above 30 kg/m2 is considered obese [16].
Statistical methods
Statistical analysis was done using statistical software ‘SPSS
version 19.0 (SPSS Inc, Chicago, IL, USA). Continuous dataTable 1 The baseline characteristics in both patient groups.
Characteristics Gro
No. (%) (total = 60) 38 (
Age (years) 65.7
Gender (No. (%)) F=
M=
BMI (kg/m2) 28 ±
Smoking Current smokers 13 (
Pack years 41 ±
PFT FEV1 (% of pred.) 40 ±
FVC (% of pred.) 87 ±
FEV1/FVC ratio 47.6
RV (% of pred.) 166
TLC (% of pred.) 127
RV/TLC ratio 48.1
ABG PaO2 (mmHg) 71 ±
PaCO2 (mmHg) 41.5
Cardiac Function LVEF (%) 61 ±
E/E0 (MV) 11.8




All results are presented as mean ± SD unless speciﬁed.
PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressu
fraction; E/E’(MV), mitral valve early ﬁlling wave in Doppler and tissue D
ND, not done.were summarized as mean with standard deviation and com-
pared between the two groups using Student’s t-test. Chi-
squared test and Fisher exact test were applied to compare
the categorical data such as sex. Pearson’s correlation coefﬁ-
cient was measured to determine the nature of associations
of Pulse wave velocity and augmentation index to other
parameters. Multiple logistic regression analysis was per-
formed to assess odds ratios of having MAU in all subjects
using aPWV quartiles as independent variables. For all analy-
ses, p value <0.05 was considered signiﬁcant and p value
<0.001 was considered highly signiﬁcant.
Results
This study included 60 patients. They were 26 females and 34
males with mean age 60.1 ± 1.8 years. They comprised 38
patients (63.3%) with COPD aged 65.7 ± 2.3 with mean
forced expiratory volume in 1 second (FEV1)% predicted
was 40.1 ± 5.6. Of the 38 patients, 13 had mild to moderate
COPD as deﬁned by the Global initiative for Chronic
Obstructive Lung Disease (GOLD COPD stage I and II
respectively) and 25 had severe and very severe COPD
(GOLD stage III and IV respectively). The mean arterial
PaO2 for patients was 72 ± 1.8 mmHg for all COPD cases.
The baseline clinical and laboratory tests of both patient
groups are shown in Table 1. Apart from pulmonary func-
tional tests, all showed no statistical signiﬁcant differences.
Table 2 shows that patients with COPD (group 1) had
increased aortic stiffness compared with matched controls.
Aortic PWV was signiﬁcantly higher in patients with COPD
compared with control subjects (11.2 ± 2.3 vs. 7.8 ± 1.5 m/
s, P< 0.05). Augmentation index was similarly increased in
patients with COPD in comparison with controls (34 ± 6.5up 1 (COPD) Group 2 (Control) P-value
63.3%) 22 (36.7%) –






5.5 25 ± 8.0 >0.05
34.2) 9 (40.9) >0.05
20 42 ± 08 >0.05
5.6 95 ± 1.3 <0.001
1.1 101 ± 6.3 >0.05
± 2.6 103 ± 5.3 <0.001
.7 ± 4.7 ND –
.6 ± 2.6 ND –
± 1.8 ND –
1.2 ND –
± 3.7 ND –
2.8 60.7 ± 6.2 >0.05
± 2.3 8.1 ± 1.8 >0.05
± 0.2 4.9 ± 0.8 >0.05
± 2.3 1.6 ± 1.7 >0.05
± 1.7 1.5 ± 0.6 >0.05
± 2.3 3.1 ± 0.1 >0.05
re of carbon dioxide in arterial blood; LVEF, left ventricle ejection
oppler; HDL, high density lipoprotein; LDL, low density lipoprotein;
Table 2 Arterial stiffness, haemodynamic measures, and






No. (%) (total = 60) 38 (63.3%) 22 (36.7%) –
eGFR (ml/min) 82 ± 9.7 91 ± 12 >0.05
MAU (mg/g) 96 ± 1.1 22 ± 1.3 <0.05
Heart rate (bpm) 70 ± 1.7 68 ± 1.9 >0.05
Peripheral SBP (mmHg) 148 ± 1.5 135 ± 2.0 >0.05
Peripheral DBP
(mmHg)
81 ± 6.1 70 ± 0.5 >0.05
Peripheral MAP
(mmHg)
108 ± 12 98 ± 1.0 >0.05
Peripheral PP (mmHg) 64 ± 6.3 57 ± 1.2 >0.05
Central SBP (mmHg) 147 ± 5.3 128 ± 8.8 >0.05
Central DBP (mmHg) 95 ± 6.3 81 ± 6.0 >0.05
Central MAP (mmHg) 83 ± 4.2 78 ± 0.4 >0.05
Central PP (mmHg) 50 ± 17 38 ± 1.1 >0.05
aPWV (m/s) 11.2 ± 2.3 7.8 ± 1.5 <0.001
Augmentation pressure
(mmHg)
25 ± 1.8 14 ± 5.8 <0.05
Augmentation index
AIx (%)
34 ± 6.5 22 ± 0.7 <0.05
Time to reﬂection (ms) 123 ± 7.8 142 ± 1.2 >0.05
All results are presented as mean ± SD.
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP,
mean arterial pressure; PP, pulse pressure.
Aortic stiffness and microalbuminuria in patients with COPD 545vs. 22 ± 0.7%, P< 0.05). Consistent with these ﬁndings the
time to wave reﬂection was reduced, although this difference
was not statistically signiﬁcant (123 ± 7.8 vs. 142 ± 1.2 ms,
P> 0.05). Table 2 also shows that there were no signiﬁcant
differences in systemic systolic BP, diastolic BP or mean
arterial pressure (MAP) between COPD patients and control
subjects. Central BP indices also showed no signiﬁcant differ-
ences. Regarding renal biomarkers, the eGFR was comparable
in COPD patients and controls (68 ± 9.7 and 76 ± 12 ml/min
respectively, p> 0.05). However, the MAU was signiﬁcantly
greater in patients than controls (96 ± 1.1 and 22 ± 1.3 mg/
g creatinine respectively, p< 0.05).
Table 3 and Fig. 3 show the signiﬁcant increased aPWV in
patients with either GOLD I and II or those with GOLD III
and IV compared to that of the healthy controls (p< 0.05).
Additionally, patients with GOLD III and IV had signiﬁcantly
higher aPWV values as compared to patients with GOLD ITable 3 Cardiovascular parameters in both patient groups and acc
Parameters (total = 60) Group 1 (COPD) 38 (63.3%)
GOLD I and II GOLD III and IV
No. (%) 13 (21.7%) 25 (41.7%)
aPWV (m/s) 9.5 ± 4.1 13.6 ± 3.6
AIx (%) 28 ± 1.5 39 ± 1.8
E/E0 (MV) 10.7 ± 0.1 11.2 ± 3.7
P1, comparison of GOLD I and GOLD II patients with GOLD III and G
with control group, P3, comparison of GOLD III and GOLD IV patienand II (p< 0.05). Regarding Augmentation index, patients
with GOLD III and IV had signiﬁcantly higher indices when
compared with either patients with GOLD I and II or with
the healthy controls (Table 3 and Fig. 4). Patients with
GOLD I and II had higher AIx values as compared to the
healthy controls, although this difference was not statistically
signiﬁcant (p> 0.05). Table 3 also shows a high incidence of
LVDD (E/E0) in patients with COPD than in control subjects
although this difference was not statistically signiﬁcant, even
there was no difference among different stages of COPD.
Table 4 shows Pearson correlation analysis between the
results of aPWV and different parameters of the patients with
COPD (group 1). aPWV did not show any correlation either
with smoking pack years, or with BMI (all p> 0.05).
However, there were signiﬁcant negative correlations between
aPWV and age (p< 0.05, r: 0.31), the partial pressure of
oxygen in arterial blood (PaO2) (p< 0.05, r: 0.35) and
between aPWV and FEV1 levels (p< 0.001, r: 0.58).
Regarding the other pulmonary function parameters, FVC
showed a weak negative and insigniﬁcant correlation with
aPWV (p> 0.05, r: 0.14), where the RV/TLC ratio showed
a moderate negative and signiﬁcant correlation (p< 0.001, r:
0.31). We did not ﬁnd a signiﬁcant correlation between
aPWV and PaCO2 (mmHg) levels in this study (p< 0.05, r:
0.21), or between aPWV and SaO2, (p< 0.05, r: 0.06). In
COPD patients, there was a signiﬁcant inverse relationship
between AIx and FEV1 (p< 0.05, r: 0.43). A similar
relationship was found between AIx and PaO2 (p< 0.05, r:
0.33). There was no relationship between AIx and other lung
functions. Interestingly, we found signiﬁcant correlations
between LVDD (E/E0) and aPWV and Aix (p< 0.05, r:
0.42 and p< 0.05, r: 0.37 respectively).
Table 5 shows the impact of COPD on the association
between aPWV and MAU. We found that adjusted odds ratios
were much higher among patients with high aPWV having
MAU after adjusting for age, BMI, MAP, and smoking.
Multiple logistic regression analyses revealed that the adjusted
odds ratios of having MAU for aPWV quartile III and IV were
6.38 (95% conﬁdence interval: 2.37–13.2) and 6.58 (95% con-
ﬁdence interval: 1.59–22.0) respectively, p< 0.05.
Discussion
There is growing evidence that chronic obstructive pulmonary
disease (COPD) and cardiovascular disease (CVD) coexist.
Many studies [17–19] proved the importance of aortic stiffness
as a predictor of cardiovascular co-morbidity in patients withording to GOLD staging of COPD.
Group 2 (Controls) P-value
P1 P2 P3
22 (36.7%) – – –
7.8 ± 1.5 <0.05 <0.05 <0.05
22 ± 0.7 <0.05 >0.05 <0.05
8.1 ± 1.8 >0.05 >0.05 >0.05
OLD IV patients. P2, comparison of GOLD I and GOLD II patients



















P < 0.05P < 0.05


















Figure 4 Augmentation index (AIx) in both patient groups according to GOLD staging of COPD.
546 A. Refaat et al.COPD. In future, chest physicians may need to measure arter-
ial pulse wave velocity in routine clinical practice.
In this study we used a vicorder machine to measure aortic
stiffness. We found that Aortic PWV was signiﬁcantly higher
in patients with COPD compared with control smoker
subjects. Augmentation index is a measure of the aug-
mentation of central blood pressure in systole by reﬂected pres-
sure waves from the peripheral arteries. We established that
augmentation index was similarly increased in patients with
COPD. Moreover, we evaluate the relationship between
obstructive lung function and central arterial stiffness. We
observed higher aPWV values in COPD patients with greater
disease severity as compared to that of patients with mild
and moderate disease forms. In Pearson correlation model,
our results showed that FEV1 were signiﬁcantly negatively
correlated to aPWV, suggesting that pulmonary obstructive
disorders may be implicated in arterial function stem or at
least both sharing the same physiopathologic processes.Another possible explanation for our results is that inﬂamma-
tory mechanisms may act as a contributing factor to both vas-
cular stiffness and obstructive lung function.
In accordance with our results, McAllister et al. [20] con-
ﬁrmed that aortic stiffness is increased in patients with
COPD which had statistically signiﬁcant associations with
FEV1 (% predicted). Also, they showed that aPWV was higher
in patients with severe and very severe COPD (GOLD stage 3
and 4) than in those with mild and moderate disease (GOLD
stage 1 and 2). Sabit et al. [21] included 75 patients with stable
COPD, and 42 healthy smokers and ex-smokers as control
subjects. They observed greater mean aPWV in the COPD
patients as compared to control subjects (11.4 ± 2.7 vs
8.95 ± 1.7 m/s, p< 0.001). Furthermore, like our results,
aPWV was correlated to the GOLD stage, thereby indicating
that the more severe airﬂow limitations are associated with
higher PWV values. Interestingly, in the Sabit et al. study, a
signiﬁcant correlation was found between IL-6 and aPWV
Table 4 Pearson correlation between parameters of the
patients in group 1 (with COPD) and aortic pulse wave






r-Value P-value r-Value P-value
Age (year) 0.31 <0.05 0.18 >0.05
Smoking (pack-year) 0.09 >0.05 0.02 >0.05
BMI (kg/m2) 0.16 >0.05 0.08 >0.05
SGRQ score 0.07 >0.05 0.13 >0.05
MAP(mmHg) 0.15 >0.05 0.22 >0.05
PFT FEV1 (% of pred.) 0.58 <0.001 0.43 <0.05
FVC (% of pred.) 0.14 >0.05 0.02 >0.05
RV (% of pred.) 0.22 >0.05 0.18 >0.05
TLC (% of pred.) 0.28 >0.05 0.20 >0.05
RV/TLC ratio 0.31 <0.05 0.17 >0.05
ABG pH 0.13 >0.05 0.29 >0.05
PaO2 (mmHg) 0.35 <0.05 0.33 <0.05
PaCO2 (mmHg) 0.21 >0.05 0.16 >0.05
SaO2 0.06 >0.05 0.11 >0.05
MAU (mg/g) 0.38 <0.05 0.35 <0.05
E/E0 (MV) 0.42 <0.05 0.37 <0.05
r-Value; correlation coefﬁcient.
SGRQ, St George’s Respiratory Questionnaire.
Aortic stiffness and microalbuminuria in patients with COPD 547and accordingly systemic inﬂammation may contribute to the
increased aortic stiffness found in patients with COPD.
The association of impaired pulmonary function with aortic
stiffness has also been reported in other studies. Zureik et al.
[22] observed reduced pulmonary function in association with
aortic stiffness in male patients free of cardiovascular diseases.
They found that aPWV was negatively associated with FEV1
even after adjustment for age, height and other cardiovascular
risk factors. Taneda et al [23] were unable to ﬁnd association of
abnormal lung function with aPWV in 678 Japanese Americans
Subjects whereas abnormal lung function deﬁned as
FVC%< 80% of predicted or FEV1%< 80% of predicted.Table 5 Odds ratios of having MAU using aPWV quartiles as inde
logistic regression analysis.






Quartile 1 (<10.2 m/s)
no. = 13
2.21 (0.78–13.7) 2.01
Quartile 2 (10.2–13.7 m/s)
no. = 14
3.23 (0.80–61.7) 2.08
Quartile 3 (13.7–15.2 m/s)
no. = 18
6.58 (1.59–22.0) § 3.75
Quartile 4 (>15.2 m/s)
no. = 15
6.38 (2.37–13.2) § 3.87
Odds ratio was adjusted for age, BMI, MAP, smoking and PaO2.
All results presented odds ratios with 95% conﬁdence interval (lower lim
§p< 0.05.On the contrary, other studies [24,25] suggested that aortic stiff-
ness may cause restriction of pulmonary function. Stiffening of
the aorta can increase left ventricular pulsatile work and is
associated with left ventricular dysfunction that could be corre-
lated to abnormal pulmonary function. In this study we also
observed correlation of lung hyperinﬂation parameters to
aPWV. Stone et al. [26] included patients with a substantial
degree of lung hyperinﬂation, with mean RV% values of
163.9%. They found no signiﬁcant correlation between the
extent of lung hyperinﬂation and aortic stiffness measurements
regardless of which parameter for measuring lung hyperinﬂa-
tion was adopted like TLC or Inspiratory capacity (IC)/TLC.
In this study, COPD patients had a signiﬁcant increase in
MAU levels compared to controls, which was positively corre-
lated to the increased aortic stiffness. Moreover, we proved
that MAU is independently related to aortic stiffness in those
patients with COPD. MAU increase would underline the
glomerular damage leading to increased permeability in
patients with increased aortic stiffness mediated via systemic
inﬂammation, hypoxaemia, or increased sympathetic activa-
tion, all known to be affected in COPD, which can open the
possibility of assessing new potential therapeutic strategies,
such as statins [27], ACE inhibitors [28] beta blockers [29] in
COPD management. It is important in this study that we
evaluated the relationship of microvasculature to the macro-
vascular state in COPD.
Other previous studies have described the prevalence of
MAU in patients with COPD. Casanova et al. [6] reported a
higher prevalence of MAU in 129 patients with stable COPD
compared with 51 control smokers with normal spirometry
without known cardiovascular disease. MAB was observed
in 24% of the patients compared with 6% of non-COPD con-
trol subjects. The MAU levels were inversely related to PaO2
and positively with the alveolar-PaO2 gradient. In Polatli
et al. study [30], 33 patients with stable COPD, 26 patients with
exacerbation, and 16 healthy subjects were assessed. The level
of MAU was signiﬁcantly increased only in the group with
exacerbation. However, in the stable COPD group, the level
of MAU was double than that of the control group. These








(0.56–8.01) 1.39 (0.15–34.9) 1.33 (0.08–3.91)
(0.59–3.12) 1.41 (0.11–2.01) 1.02 (0.50–2.33)
(1.08–5.91) 3.65 (1.87–5.92) 2.01 (1.26–4.03)
(1.63–4.09) 3.78 (0.55–34.9) 3.24 (1.88–5.91)
it-upper limit).
548 A. Refaat et al.appears to increase during exacerbations. In study of John
et al. [8] 52 patients with COPD and 34 control smokers were
included. All of them underwent spirometry, blood pressure,
aPWV and a spot urine examination for MAU, with other
renal biomarkers like serum kidney injury molecule and cys-
tatin. They could prove the occurrence of glomerular damage
in patients with COPD as evidenced by increased MAU,
related to increased aortic stiffness, suggested that microvascu-
lar state in COPD management should be considered.
The present study observed incidence of LVDD in patients
with COPD but there was no difference among different stages
of COPD. In agreement with these results, Boussuges et al [31]
found a high incidence of LVDD in patients with COPD. A
recent study of Caram et al. [32] showed more frequent
echocardiographic ﬁndings of mild LVDD in COPD patients,
independently of COPD stage. Another recent study [33]
showed a potentially highest prevalence of LVDD in patients
with severe stable COPD (FEV1of 30%–50%). The potential
pathophysiologic mechanism for the association between
COPD and LVDD could be systemic inﬂammation, which is
associated with myocardial ischaemia and LVDD. However,
in the present study, there was no correlation with stages of
COPD. Therefore, there may be some other mechanisms
involved in this process. Moreover, we found a signiﬁcant
relationship between arterial stiffness and left ventricular dia-
stolic dysfunction. Hu et al. [34] report a similar result; they
concluded that left ventricular diastolic dysfunction has a
direct relationship to arterial stiffening, independent of cardio-
vascular risk factors. Furthermore they conﬁrm the relation
between several well-known baseline characteristics and both
diastolic dysfunction and arterial stiffness. The authors con-
cluded that the severity of left ventricular diastolic dysfunction
correlates with the severity of arterial stiffness.
Conclusions
COPD is associated with increased aortic stiffness. MAU is
independently related to aortic stiffness in patients with
COPD. Further studies are necessary to investigate whether
MAU could be an effective biomarker of aortic stiffness and
potential cardiovascular compromise in patients with COPD.
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